CompletedNCT00749944
Varenicline or placebo and mood or behavior changes during smoking cessation
About this title
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
Read the official source — NCT00749944Medication studyAges 18–75United StatesSuicide prevention
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
- Listed locations
- Austin and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 110
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00749944
- Official title
Show the full official title
An Experimental Medicine, Randomized, Double-Blind Study Assessing Neuropsychiatric Symptoms In Quitting Smokers Treated With Varenicline Tartrate Or Placebo
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Austin · San Antonio
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including varenicline and placebo.
Who was this study for?
Listed age limits: 18 years to 75 years.
